Commercial Denali sells FDA voucher for $195M to support neurodegenerative pipeline BioSpaceDenali Therapeutics is the latest company to sell a priority review fast pass for an elevated price after the program was renewed earlier this year.NeuroscienceRead full story pharminent June 19, 2026 (Last updated: June 22, 2026) BioSpace Denali Therapeutics is the latest company to sell a priority review fast pass for an elevated price after the program was renewed earlier this year. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: US launches probe of German ‘underpayment’ for medicinesNext: Japan approves Sanofi’s Sarclisa combo for MM treatment Related Stories Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026 Commercial Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval pharminent June 26, 2026
